These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15963209)

  • 41. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ; Prentice NP; Cousland G; Bonham J
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):155-60. PubMed ID: 17600848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.
    McDermott CL; Gray SL
    Ann Pharmacother; 2012 Apr; 46(4):599-605. PubMed ID: 22414791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Donepezil for Alzheimer's disease.
    Benjamin B; Burns A
    Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
    Seltzer B
    J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
    Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
    Kavanagh S; Van Baelen B; Schäuble B
    J Alzheimers Dis; 2011; 27(3):521-30. PubMed ID: 21891871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.
    Van Puyvelde K; Mets T;
    Geriatr Gerontol Int; 2011 Jul; 11(3):256-61. PubMed ID: 21199235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
    Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
    Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M
    Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on Alzheimer drugs (donepezil).
    Smith Doody R
    Neurologist; 2003 Sep; 9(5):225-9. PubMed ID: 12971832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
    Caffarra P; Vezzadini G; Copelli S; Dieci F; Messa G; Nonis E; Venneri A
    Acta Biomed; 2007; 78(1):16-21. PubMed ID: 17687812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Verbal repetition in patients with Alzheimer's disease who receive donepezil.
    Asp E; Cloutier F; Fay S; Cook C; Robertson ML; Fisk J; Dei DW; Rockwood K
    Int J Geriatr Psychiatry; 2006 May; 21(5):426-31. PubMed ID: 16676290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drugs used for cognitive symptoms of Alzheimer's disease.
    Keltner NL; Zielinski AL; Hardin MS
    Perspect Psychiatr Care; 2001; 37(1):31-4. PubMed ID: 15521137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.